Dysregulated proteins in osteoarthritis joint tissue

Dysregulated proteins in osteoarthritis joint tissue refers to the collective set of proteins that show significant differential expression or activity in the cartilage, synovium, and subchondral bone of patients with osteoarthritis (OA). This group includes catabolic enzymes like Matrix metalloproteinase-13 (MMP-13) and ADAMTS-5, which are primary drivers of extracellular matrix degradation (Source: PubMed/PMID: 23645158). It also encompasses pro-inflammatory cytokines such as Interleukin-1 beta (IL-1β) and Tumor necrosis factor-alpha (TNF-α) that promote chondrocyte apoptosis and synovial inflammation (Source: NIH/NIAMS). Because this term describes a broad proteomic profile rather than a single molecule, it is used in research to identify specific therapeutic targets and diagnostic biomarkers. Drugs targeting specific members of this group, such as cytokine inhibitors or matrix-stabilizing agents, aim to modify the disease course or manage chronic pain associated with joint degeneration (Source: StatPearls).

Other names

Osteoarthritis-associated proteomeOA joint tissue dysregulated proteinsOsteoarthritis synovial fluid proteinsOA cartilage proteome

Inhibition of catabolic enzymes (e.g., MMPs), neutralization of pro-inflammatory cytokines (e.g., IL-1, TNF), and modulation of nerve growth factors to alleviate pain and reduce cartilage degradation.